» Articles » PMID: 19247211

68Ga-DOTA-NOC: a New PET Tracer for Evaluating Patients with Bronchial Carcinoid

Overview
Journal Nucl Med Commun
Specialty Nuclear Medicine
Date 2009 Feb 28
PMID 19247211
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Conventional imaging techniques [computed tomography (CT), ultrasound, magnetic resonance] and somatostatin receptor scintigraphy are often insufficient to make a conclusive diagnosis of bronchial carcinoid (BC). PET is commonly used for the assessment of lung cancer but 18F-fluorodeoxyglucose, the most frequently used PET tracer, presents a low sensitivity for the detection of neuroendocrine tumours (NETs). New PET radiopharmaceuticals such as 68Ga-DOTA peptides, which directly bind to somatostatin receptors and are usually expressed on NET cell surfaces, have been reported to be superior to both morphological and somatostatin receptor scintigraphy imaging for gastroenteropancreatic NETs. However, their role in BC has never been evaluated. Our aim is to evaluate the role of 68Ga-DOTA-NOC (68Ga-labelled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-Nal3-octreotide) PET for the assessment of BC patients.

Methods: Ten patients with pathologically proven well-differentiated BC and one patient with highly suggestive CT images for BC were studied by 68Ga-DOTA-NOC PET/CT. PET findings were compared with clinical follow-up, pathology and contrast-enhanced CT findings.

Results: 68Ga-DOTA-NOC PET/CT detected at least one lesion in nine of 11 patients and was negative in two. PET/CT and contrast-enhanced CT were discordant in eight of 11 patients, whereas in only three patients both provided similar results. PET/CT detected a higher number of lesions in five patients and excluded malignancy at sites considered positive on CT in three of 11; follow-up confirmed PET/CT findings in all patients. In PET/CT-positive patients, the mean maximal standardized uptake value was 25.9 [4.4-60.5]. On a clinical basis, PET/CT provided additional information in nine of 11 patients leading to the changes in the clinical management of three of nine patients.

Conclusion: PET/CT with Ga-DOTA-NOC was useful in BC patients because it led to a better evaluation of the extent of the disease.

Citing Articles

A Systematic Review on Combined [F]FDG and Ga-SSA PET/CT in Pulmonary Carcinoid.

Prosperi D, Carideo L, Russo V, Meucci R, Campagna G, Lastoria S J Clin Med. 2023; 12(11).

PMID: 37297914 PMC: 10253705. DOI: 10.3390/jcm12113719.


Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT.

Trotter J, Pantel A, Teo B, Escorcia F, Li T, Pryma D Adv Radiat Oncol. 2023; 8(5):101212.

PMID: 37197709 PMC: 10184051. DOI: 10.1016/j.adro.2023.101212.


Value of [Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.

Deleu A, Laenen A, Decaluwe H, Weynand B, Dooms C, De Wever W EJNMMI Res. 2022; 12(1):28.

PMID: 35524900 PMC: 9079198. DOI: 10.1186/s13550-022-00900-3.


Coexistence of Multiple Metastatic Lesions Showing Various Grades of Differentiation in a Single Patient with Neuroendocrine Tumor of Lung as Primary: A Combined Modality Approach of Ga-DOTANOC Positron Emission Tomography/Computed Tomography and....

Tripathy S, Ballal S, Yadav M, Joshi P, Bal C, Damle N Indian J Nucl Med. 2019; 34(3):260-262.

PMID: 31293318 PMC: 6593945. DOI: 10.4103/ijnm.IJNM_161_18.


Novel PET tracers: added value for endocrine disorders.

Bergeret S, Charbit J, Ansquer C, Bera G, Chanson P, Lussey-Lepoutre C Endocrine. 2019; 64(1):14-30.

PMID: 30875057 DOI: 10.1007/s12020-019-01895-z.